Journal article
Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells
Cancer Immunology, Immunotherapy, Vol.62(4), pp.677-687
04/2013
DOI: 10.1007/s00262-012-1368-4
PMCID: PMC3639312
PMID: 23151944
Abstract
Human γδ T cells display potent cytotoxicity against various tumor cells pretreated with zoledronic acid (Zol). Zol has shown benefits when added to adjuvant endocrine therapy for patients with early-stage breast cancer or to standard chemotherapy for patients with multiple myeloma. Although γδ T cells may contribute to this additive effect, the responsiveness of γδ T cells from early-stage breast cancer patients has not been fully investigated. In this study, we determined the number, frequency, and responsiveness of Vγ2Vδ2 T cells from early- and late-stage breast cancer patients and examined the effect of IL-18 on their ex vivo expansion. The responsiveness of Vγ2Vδ2 T cells from patients with low frequencies of Vγ2Vδ2 T cells was significantly diminished. IL-18, however, enhanced ex vivo proliferative responses of Vγ2Vδ2 T cells and helper NK cells from patients with either low or high frequencies of Vγ2Vδ2 T cells. Treatment of breast cancer patients with Zol alone decreased the number of Vγ2Vδ2 T cells and reduced their ex vivo responsiveness. These results demonstrate that Zol can elicit immunological responses by γδ T cells from early-stage breast cancer patients, but that frequent in vivo treatment reduces Vγ2Vδ2 T cell numbers and their responsiveness to stimulation.
Details
- Title: Subtitle
- Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells
- Creators
- Tomoharu Sugie - Department of Surgery, Graduate School of Medicine Kyoto University Yoshidakonoe-cho, Sakyo-ku Kyoto 606-8501 JapanKaoru Murata-Hirai - Center for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine Kyoto University Yoshidakonoe-cho, Sakyo-ku Kyoto 606-8501 JapanMasashi Iwasaki - Department of Immunology and Cell Biology, Graduate School of Medicine Kyoto University Yoshidakonoe-cho, Sakyo-ku Kyoto 606-8501 JapanCraig Morita - Department of Internal Medicine and the Interdisciplinary Graduate Program in Immunology University of Iowa Carver College of Medicine, Veterans Affairs Health Care System, EMRB 400F Iowa City IA 52242-1101 USAWen Li - Tumor Immunology and Cell Therapy, Hyogo College of Medicine 1-1 Mukogawa-cho Nishinomiya Hyogo 663-8501 JapanHaruki Okamura - Tumor Immunology and Cell Therapy, Hyogo College of Medicine 1-1 Mukogawa-cho Nishinomiya Hyogo 663-8501 JapanNagahiro Minato - Department of Immunology and Cell Biology, Graduate School of Medicine Kyoto University Yoshidakonoe-cho, Sakyo-ku Kyoto 606-8501 JapanMasakazu Toi - Department of Surgery, Graduate School of Medicine Kyoto University Yoshidakonoe-cho, Sakyo-ku Kyoto 606-8501 JapanYoshimasa Tanaka - Center for Therapeutic Innovation, Graduate School of Biomedical Sciences Nagasaki University 1-14 Bunkyo-machi Nagasaki 852-8521 Japan
- Resource Type
- Journal article
- Publication Details
- Cancer Immunology, Immunotherapy, Vol.62(4), pp.677-687
- DOI
- 10.1007/s00262-012-1368-4
- PMID
- 23151944
- PMCID
- PMC3639312
- NLM abbreviation
- Cancer Immunol Immunother
- ISSN
- 0340-7004
- eISSN
- 1432-0851
- Publisher
- Springer-Verlag
- Language
- English
- Date published
- 04/2013
- Academic Unit
- Immunology; Internal Medicine
- Record Identifier
- 9984094570602771
Metrics
19 Record Views